Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary Mirati Therapeutics To Participate In Oncology Panels At The 2018 Citi Biotech Conference
SAN DIEGO , Aug. 29, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two panel discussions, at the 2018 Citi Biotech Conference in Boston . Charles M. Baum , M.D., Ph.D., President and Chief Executive Officer will
View HTML
Toggle Summary Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
SAN DIEGO , Aug. 16, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced that a KRAS G12C poster will be presented by scientists from Mirati and Array BioPharma at the 255 th American Chemical Society (ACS) National Meeting &
View HTML
Toggle Summary Mirati Therapeutics Reports Second Quarter Financial Results
SAN DIEGO , Aug. 1, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2018 . "In June we successfully completed a financing, with net proceeds of $130.7 million ,
View HTML
Toggle Summary Mirati Therapeutics To Present Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress
SAN DIEGO , July 24, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that two abstracts highlighting data from ongoing clinical studies of sitravatinib will be presented as Proffered Papers in oral presentations at the 2018
View HTML
Toggle Summary Mirati Therapeutics Added to Russell 2000® Index
SAN DIEGO , June 25, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has been added to the Russell 2000 ® Index, effective as of the open of the market on Monday, June 25, 2018 , following Russell's annual
View HTML
Toggle Summary Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , June 11, 2018 /PRNewswire/ --   Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the closing of its previously announced underwritten public offering of 3,162,500 shares of its common stock at a public offering price of $38.85 per share representing no discount to the last
View HTML
Toggle Summary Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
SAN DIEGO , June 7, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 2,750,000 shares of its common stock at a price to the public of $38.85 per share. In addition, and in lieu of common stock, Mirati is offering to
View HTML
Toggle Summary Mirati Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO , June 6, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional 15% of
View HTML
Toggle Summary Mirati To Present New Data In Renal Cell Carcinoma From Ongoing Phase 1b Clinical Trial Of Single Agent Sitravatinib At The 2018 ASCO Annual Meeting
SAN DIEGO , May 31, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced that new data from the ongoing Phase 1b clinical trial of single agent sitravatinib will be presented at the 2018 American Society of Clinical Oncology ( ASCO )
View HTML
Toggle Summary Mirati Therapeutics To Present At Jefferies 2018 Global Healthcare Conference
SAN DIEGO , May 30, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the Jefferies Annual Global Healthcare Conference in New York on Friday, June 8 th at 8:30 a.m. ET / 5:30 a.m. PT . Charles M.
View HTML